publication date: Apr. 1, 2016

The Tivozanib Timeline 


December 2008, May 2009

End-of-phase II meetings between AVEO Pharmaceuticals Inc. and FDA result in agreement concerning the design of the phase III trial of tivozanib for advanced renal cell carcinoma.

During the December 2008 meeting, the agency and AVEO discuss several study designs and FDA states that “a substantial, robust improvement in PFS that is clinically meaningful and statistically persuasive may be considered for regulatory decision.”

FDA also states that “a statistically significant improvement in OS is not required for regulatory approval, but a pre-specified OS analysis plan is still helpful in the regulatory decision making process.”

In the May 2009 meeting, the agency and AVEO discuss the final phase III protocol. Crossover design is not discussed and is not included in the phase III study itself (a later protocol added the crossover). See the FDA briefing documents for ODAC.

According to, the study’s estimated completion date—defined as final collection date for primary outcome measure—is December 2011.


June 9, 2011

Ronald DePinho, co-founder of AVEO and member of the company’s board of directors, is named president of MD Anderson Cancer Center. His wife, Lynda Chin, an AVEO co-founder, joins MD Anderson as a senior scientist.


April 16, 2012

AVEO says the TIVO-1 pivotal … Continue reading 42-13 The Tivozanib Timeline

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.